Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic stem cell transplantation (Northwestern University protocol)
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A non-myeloablative autologous hematopoietic stem cell transplantation (HSCT) protocol developed at Northwestern University for the treatment of relapsing-remitting multiple sclerosis (RRMS). The procedure involves mobilizing a patient's own peripheral blood stem cells using cyclophosphamide and granulocyte colony-stimulating factor (G-CSF). This is followed by a conditioning regimen consisting of high-dose cyclophosphamide (200 mg/kg) and alemtuzumab (CAMPATH-1H, 20 mg) to deplete the autoreactive immune system. Finally, the harvested stem cells are re-infused to facilitate immune reconstitution and the establishment of a self-tolerant immune system. The protocol is specifically designed for patients who have failed conventional therapies, such as interferon, and aims to halt inflammatory activity and disease progression.
- Other names
- Northwestern HSCT protocolNon-myeloablative HSCT for MSBurt protocolhematopoietic stem cell transplantation-Northwestern University-multiple sclerosis
Beyond the preview
Go deeper on autologous hematopoietic stem cell transplantation (Northwestern University protocol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic stem cell transplantation (Northwestern University protocol).